Cargando…

Targeted repositioning identifies drugs that increase fibroblast growth factor 20 production and protect against 6-hydroxydopamine-induced nigral cell loss in rats

Endogenous fibroblast growth factor 20 (FGF20) supports maintenance of dopaminergic neurones within the nigrostriatal pathway. Moreover, direct intracerebral infusion of FGF20 protects against nigrostriatal tract loss in the 6-hydroxydopamine lesion rat model of Parkinson’s disease. Increasing endog...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fletcher, Edward J. R., Jamieson, Aran D., Williams, Gareth, Doherty, Patrick, Duty, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554393/ https://www.ncbi.nlm.nih.gov/pubmed/31171821 http://dx.doi.org/10.1038/s41598-019-44803-1

Ejemplares similares

Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson’s disease
por: Fletcher, Edward J. R., et al.
Publicado: (2019)

Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner
por: Boshoff, Eugene.L., et al.
Publicado: (2018)

Application of the Physical Disector Principle for Quantification of Dopaminergic Neuronal Loss in a Rat 6-Hydroxydopamine Nigral Lesion Model of Parkinson's Disease
por: Fabricius, Katrine, et al.
Publicado: (2017)

Epothilone B Benefits Nigral Dopaminergic Neurons by Attenuating Microglia Activation in the 6-Hydroxydopamine Lesion Mouse Model of Parkinson’s Disease
por: Yu, Zhongyuan, et al.
Publicado: (2018)

Activation of GSK-3β and Caspase-3 Occurs in Nigral Dopamine Neurons during the Development of Apoptosis Activated by a Striatal Injection of 6-Hydroxydopamine
por: Hernandez-Baltazar, Daniel, et al.
Publicado: (2013)

Drug repurposing strategies of relevance for Parkinson’s disease
por: Fletcher, Edward J. R., et al.
Publicado: (2021)

Nigral volume loss in prodromal, early, and moderate Parkinson’s disease
por: Langley, Jason, et al.
Publicado: (2023)

Application of flavonoids for the protection of nigral dopaminergic neurons from oxidative stress
por: Kim, Sang Ryong
Publicado: (2020)

Down-regulation of microglial activity attenuates axotomized nigral dopaminergic neuronal cell loss
por: Song, Dae-Yong, et al.
Publicado: (2013)

Heptachlor induced nigral dopaminergic neuronal loss and Parkinsonism-like movement deficits in mice
por: Hong, Seokheon, et al.
Publicado: (2014)

Upregulation of neuronal astrocyte elevated gene-1 protects nigral dopaminergic neurons in vivo
por: Leem, Eunju, et al.
Publicado: (2018)

Nigral iron deposition in common tremor disorders
por: Homayoon, Nina, et al.
Publicado: (2018)

Discovery of nigral dopaminergic neurogenesis in adult mice
por: Morrison, Brad E.
Publicado: (2016)

Height and nigral neuron density in Parkinson’s disease
por: Saari, Laura, et al.
Publicado: (2022)

Inhibition of Nigral Microglial Activation Reduces Age-Related Loss of Dopaminergic Neurons and Motor Deficits
por: Wang, Tzu-Feng, et al.
Publicado: (2022)

Chronic Spinal Cord Electrical Stimulation Protects Against 6-hydroxydopamine Lesions
por: Yadav, Amol P., et al.
Publicado: (2014)

The 1-Tosylpentan-3-one Protects against 6-Hydroxydopamine-Induced Neurotoxicity
por: Kao, Chien-Jen, et al.
Publicado: (2017)

Paeonol Protection Against Intrastriatal 6-Hydroxydopamine Rat Model of Parkinson’s Disease
por: Ghalami, Jamileh, et al.
Publicado: (2021)

Human Albumin Prevents 6-Hydroxydopamine-Induced Loss of Tyrosine Hydroxylase in In Vitro and In Vivo
por: Zhang, Li-Juan, et al.
Publicado: (2012)

Protective efficacy of P7C3-S243 in the 6-hydroxydopamine model of Parkinson's disease
por: De Jesús-Cortés, Héctor, et al.
Publicado: (2015)

PROMISCUOUS 2.0: a resource for drug-repositioning
por: Gallo, Kathleen, et al.
Publicado: (2020)

Methanolic Extract of Boswellia serrata Gum Protects the Nigral Dopaminergic Neurons from Rotenone-Induced Neurotoxicity
por: Shadfar, Sina, et al.
Publicado: (2022)

Drug Repositioning: An Opportunity to Develop Novel Treatments for Alzheimer’s Disease
por: Corbett, Anne, et al.
Publicado: (2013)

Impact of age and vector construct on striatal and nigral transgene expression
por: Polinski, Nicole K, et al.
Publicado: (2016)

Effects of Subthalamic and Nigral Stimulation on Gait Kinematics in Parkinson’s Disease
por: Scholten, Marlieke, et al.
Publicado: (2017)

Reversing Parkinson Disease Model with in situ Converted Nigral Neurons
por: Qian, Hao, et al.
Publicado: (2020)

Impact of simultaneous subthalamic and nigral stimulation on dysphagia in Parkinson’s disease
por: Pflug, Christina, et al.
Publicado: (2020)

Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease
por: Heilman, Patrick L., et al.
Publicado: (2020)

Subthalamic and nigral neurons are differentially modulated during parkinsonian gait
por: Gulberti, Alessandro, et al.
Publicado: (2023)

Substantia nigral dopamine transporter uptake in dementia with Lewy bodies
por: Lee, Young-gun, et al.
Publicado: (2023)

Activin A Protects Midbrain Neurons in the 6-Hydroxydopamine Mouse Model of Parkinson’s Disease
por: Stayte, Sandy, et al.
Publicado: (2015)

Protection of nigral dopaminergic neurons by AAV1 transduction with Rheb(S16H) against neurotoxic inflammation in vivo
por: Kim, Sehwan, et al.
Publicado: (2018)

Efficient Sustained-Release Nanoparticle Delivery System Protects Nigral Neurons in a Toxin Model of Parkinson’s Disease
por: Wang, Qun, et al.
Publicado: (2022)

Animal models of Parkinson’s disease: a guide to selecting the optimal model for your research
por: Lama, Joana, et al.
Publicado: (2021)

The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice
por: Migdalska-Richards, Anna, et al.
Publicado: (2017)

Is there a special relationship between complex I activity and nigral neuronal loss in Parkinson’s disease? A critical reappraisal
por: Subrahmanian, Nitya, et al.
Publicado: (2021)

Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons
por: Benner, Eric J., et al.
Publicado: (2008)

Glutathione depletion and overproduction both initiate degeneration of nigral dopaminergic neurons
por: Garrido, Manuel, et al.
Publicado: (2010)

Subthalamic Nucleus Electrical Stimulation Modulates Calcium Activity of Nigral Astrocytes
por: Barat, Elodie, et al.
Publicado: (2012)

Multi-facetted impulsivity following nigral degeneration and dopamine replacement therapy
por: Engeln, Michel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_ae72j63uo9ja9oa67vrrsfujtd